NASDAQ:MIST Milestone Pharmaceuticals Q3 2025 Earnings Report $0.92 +0.00 (+0.22%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Milestone Pharmaceuticals EPS ResultsActual EPS-$0.12Consensus EPS -$0.17Beat/MissBeat by +$0.05One Year Ago EPSN/AMilestone Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMilestone Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time7:00AM ETUpcoming EarningsMilestone Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings ReleaseQuarterly Report(10-Q) Milestone Pharmaceuticals Earnings HeadlinesMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 21 at 2:15 AM | americanbankingnews.comMilestone Wins China Approval for Etripamil Nasal SpraySeptember 4, 2026 | theglobeandmail.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 21 at 1:00 AM | Weiss Ratings (Ad)Milestone Wins NMPA Approval For Etripamil Nasal Spray In PSVTSeptember 3, 2026 | rttnews.comMilestone Gets China Approval For Etripamil Nasal SpraySeptember 3, 2026 | rttnews.comMilestone Pharmaceuticals Announces China NMPA Approval of Etripamil for PSVT, Triggering $2 Million Milestone PaymentSeptember 3, 2026 | quiverquant.comQSee More Milestone Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email. Email Address About Milestone PharmaceuticalsMilestone Pharmaceuticals (NASDAQ:MIST) is a biopharmaceutical company focused on developing therapies for cardiovascular conditions. The company’s lead product is etripamil, a short-acting, non-dihydropyridine calcium channel blocker formulated as a self-administered nasal spray. Etripamil has been developed primarily for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT), a form of abnormally fast heart rhythm that can begin and end suddenly. Milestone has also evaluated the therapy in other cardiovascular applications, including the potential treatment of angina and related conditions. Founded in 2012, Milestone is headquartered in Montreal, Quebec, and has conducted clinical development activities in North America. The company is led by Joseph Oliveto, who serves as president and chief executive officer.View Milestone Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
